Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.

Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, Kato Y, Crotty EG, Kim C, Rawlings SA, Mateus J, Tse LPV, Frazier A, Baric R, Peters B, Greenbaum J, Saphire EO, Smith DM, Sette A, Crotty S. · 2020

Read Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. by Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, Kato Y, Crotty EG, Kim C, Rawlings SA, Mateus J, Tse LPV, Frazier A, Baric R, Peters B, Greenbaum J, Saphire EO, Smith DM, Sette A, Crotty S. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7494270.txt.

Introduction

Rydyznski Moderbacher and co-authors examine adaptive immunity in acute COVID-19 and its links with age and severity. Knowledge of antigen-specific responses was thin. The team checked all three branches of adaptive immunity at once.

They measured virus-specific CD4+ T cells, CD8+ T cells, and neutralizing antibodies in acute and healing subjects. Each T cell branch tracked with milder disease. When all three responses moved in step, disease ran milder still. That coordination broke down in people aged 65 years or more. A lack of naive T cells also came with age and poor outcomes. The authors read the pattern plainly: joined-up responses protect, while scattered ones fail. Aging can uncouple the trio that guards the body.

Catalog record

CREATORRydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, Kato Y, Crotty EG, Kim C, Rawlings SA, Mateus J, Tse LPV, Frazier A, Baric R, Peters B, Greenbaum J, Saphire EO, Smith DM, Sette A, Crotty S.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE110 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7494270

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity By Carolyn Rydyznski Moderbacher, Sydney I Ramirez, Jennifer M Dan, Alba Grifoni, Kathryn M Hastie, Daniela Weiskopf, Simon Belanger, Robert K Abbott, Christina Kim, Jinyong Choi, Yu Kato, Eleanor G Crotty Published in: Cell DOI: 10.1016/j.cell.2020.09.038 ABSTRACT Summary Limited knowledge is available on the relationship between antigen-specific immune responses and COVID-19 disease severity. We completed a combined examination of all three branches of adaptive immunity at the level of SARS-CoV-2-specific CD4+ and CD8+ T cell and neutralizing antibody responses in acute and convalescent subjects. SARS-CoV-2-specific CD4+ and CD8+ T cells were each associated with milder disease. Coordinated SARS-CoV-2-specific adaptive immune responses were associated with milder disease, suggesting roles for both CD4+ and CD8+ T cells in protective immunity in COVID-19. Notably, coordination of SARS-CoV-2 antigen-specific responses was disrupted in individuals ≥ 65 years old. Scarcity of naive T cells was also associated with aging and poor disease outcomes. A parsimonious explanation is that coordinated CD4+ T cell, CD8+ T cell, and antibody responses are protective, but uncoordinated responses frequently fail to control disease, with a connection between aging and impaired adaptive immune responses to SARS-CoV-2. Keywords: coronavirus, CD4, CD8, T cells, antibody, neutralizing antibodies, adaptive immunity, CXCL10, IP-10, Spike, epitopes INTRODUCTION The ongoing COVID-19 pandemic has resulted in the infection of nearly 18 million people worldwide within 8 months, with over 4.5 million cases in the United States (World Health Organization). While most SARS-CoV-2 infections are not severe, a significant percentage of patients require hospitalization, and many fatalities occur, with increased rates of severe and fatal disease among older individuals (> 65 years old) (Docherty et al., 2020; Grasselli et al., 2020) and those with pre-existing medical conditions like cardiovascular disease, obesity, and type 2 diabetes mellitus (Docherty et al., 2020; Richardson et al., 2020). Severe cases can progress to respiratory failure associated with diffuse alveolar damage and acute respiratory distress syndrome (ARDS) (Grasselli et al., 2020; Richardson et al., 2020), similar to what was observed for SARS (Rockx et al., 2020). The relative role(s) played by the immune response to SARS-CoV-2 versus direct viral effects in the respiratory system and other organ systems has been questioned, with the possibility of immunopathogenesis being a major causal component of severe COVID-19 (McKechnie and Blish, 2020; Vabret et al., 2020). Elevated innate immune cytokines detected in peripheral blood including interleukin (IL)-1, IL-6, IL-8, or C-X-C Motif Chemokine Ligand 10 (CXCL10) have been associated with severe or fatal COVID-19 (Blanco-Melo et al., 2020; Laing et al., 2020; Lucas et al., 2020; Vabret et al., 2020; Del Valle et al., 2020). However, insufficient information directly examining SARS-CoV-2 antigen-specific CD4+ T cells, CD8+ T cells, and neutralizing antibodies in the same acute patients is hindering our understanding of the roles of adaptive immunity in acute COVID-19 protection or pathogenesis. SARS-CoV-2 antigen-specific adaptive immune responses (ADIM) have been inferred from surrogate markers in large studies (Laing et al., 2020; Lucas et al., 2020; Mathew et al., 2020), and some antigen-specific T cell (Meckiff et al., 2020; Weiskopf et al., 2020) or neutralizing antibody data (Robbiani et al., 2020; Rogers et al., 2020; Wajnberg et al., 2020) are available, but combined assessments of antigen-specific CD4+ T cells, CD8+ T cells, and neutralizing antibodies in acute COVID-19 are still lacking (except 3 subjects in Zhou et al., 2020b). Addressing these fundamental questions is important for the clinical management of COVID-19, as well as for proper COVID-19 vaccine development cognizant of protective immune responses and potential immunopathogenic responses. The adaptive immune system responds to pathogens in an antigen-specific manner to develop protective immunity. The adaptive immune system consists of three major lymphocyte types: B cells (antibody producing cells), CD4+ T cells (helper T cells), and CD8+ T cells (cytotoxic, or killer, T cells) (Murphy and Weaver, 2016). All three arms of adaptive immunity can be important in protection against viral infections. The vast majority of licensed human vaccines work on the basis of protective antibody responses, with neutralizing antibodies being the most common mechanism of action (Piot et al., 2019; Plotkin, 2010; Plotkin et al., 2018). Thus, most COVID-19 vaccine efforts focus on the elicitation of neutralizing antibodies (Amanat and Krammer, 2020; Corey et al., 2020; Thanh Le et al., 2020), with additional interest in elicitation of CD4+ or CD8+ T cells (Corbett et al., 2020; Folegatti et al., 2020; Jackson et al., 2020; Mercado et al., 2020; Sahin et al., 2020). Almost all neutralizing antibody responses, durable antibody responses, and affinity-matured B cell memory depend on CD4+ T cell help (Crotty, 2019). As such, CD4+ T cell responses are critical to the success of most vaccines. Additionally, CD4+ T cells have a range of different functionalities beyond helping antibody responses that can be valuable in the context of antiviral immunity (Zhu et al., 2010). In a mouse model of SARS, it was demonstrated that CD4+ T cells alone, in the absence of antibodies or CD8+ T cells, could provide protection against lethal challenge with SARS-CoV (Zhao et al., 2016). Separately, extensive animal model studies have proven the importance of CD8+ T cells in protective immunity against a range of viral infections (Chang et al., 2014; Masopust and Soerens, 2019). Thus, it is important to assess all three arms of adaptive immunity in SARS-CoV-2-infected individuals across the spectrum of COVID-19 disease severity in a coordinated manner to gain insights into SARS-CoV-2 protective immunity and potential immunopathogenesis. RESULTS We set out to measure fundamental metrics of all three arms of the antigen-specific adaptive immune responses (ADIMs) to SARS-CoV-2 and then relate those antigen-specific immune responses to COVID-19 disease severity in acutely ill and convalescent individuals. In our earlier work, we measured CD4+ and CD8+ T cell responses in a cohort of average, non-hospitalized cases of COVID-19 during the convalescent phase as a first benchmark of ADIMs to SARS-CoV-2 (Grifoni et al., 2020a). That study did not include acute patients and did not include measurement of SARS-CoV-2-neutralizing antibodies. Here, we measured SARS-CoV-2-specific antibodies (including neutralizing antibodies), SARS-CoV-2-specific CD4+ T cells, and SARS-CoV-2-specific CD8+ T cells in all individuals in a new cohort, with an emphasis on including acute cases across a range of COVID-19 disease severities. 54 subjects were enrolled in this study, 24 subjects with acute COVID-19. Maximum disease severity ranged from mild to fatal (Table S1; Figure S1A). Days post-symptom onset (PSO) for sample collection ranged from d4-37 (Table S1). We also obtained a second or third blood sample from 5 subjects with acute COVID-19. Fifteen convalescent subjects and 15 unexposed control subjects were also enrolled (Table S1). SARS-CoV-2-specific antibodies, CD4+ T cells, and CD8+ T cells were each quantified by multiple methods. [Figure: SARS-CoV-2 Antibody Responses, Related to Figure 1(A) Frequency of Peak Disease Severity (1-10) for acute and convalescent COVID-19.(B-J) Plasma ELISA curves for SARS-CoV-2 spike RBD (B) IgG, (C) IgA, (D) IgM; SARS-CoV-2 Spike (E) IgG, (F) IgA, (G) IgM; and SARS-CoV-2 Nucleocapsid (N) protein (H) IgG, (I) IgA, and (J) IgM. C92 and C98 are representative acute donors. Grey lines = all other COVID-19 samples. The dotted line indicates LOD.(K) Correlation of Spike IgA with RBD IgA.(L) Correlation of N

Read the complete text